- POSITIVE
Annual Revenue Galaxy Medicare Mar-2026 Annual Revenue is Rs 41 Cr which is growth of 2.6% YoY.
- POSITIVE
Annual Net Profit Galaxy Medicare Mar-2026 Annual Net Profit is Rs 3 Cr which is growth of 1.4% YoY.
aboutGalaxy Medicare Ltd. (GML) is a provider in the medical services and pharmaceuticals sector, primarily operating through its association with other corporate entities and through direct medical service offerings. The company maintains a presence in t... Read More
18.000.00(0.00%)
8,000
NSE Volume
NSE 30 Oct, 2026 3:31 PM (IST)
Please subscribe to view forecaster data
Galaxy Medicare Stock Price Analysis
Week Price Range-0.3% 1 Week return | 18 (LTP) 17.218 LowHigh |
|---|---|
Month Price Range2.0% 1 Month return | 18 (LTP) 16.219 LowHigh |
52 Week Price Range-14.9% 1 Year return | 18 (LTP) 15.223.8 LowHigh |
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Galaxy Medicare annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 |
|---|---|---|---|---|---|---|---|---|---|---|
8.9% | 7.3% | 41.3 | 40.3 | 36.9 | 32 | 30.7 | 29 | 27.4 | ||
Operating Exp. Ann. | 7.3% | 6.3% | 35.8 | 34.6 | 31.2 | 29 | 27.4 | 26.4 | 25.3 | |
Operating Profit Ann. | 22.2% | 11.8% | 4.2 | 4.7 | 4.9 | 2.3 | 2.5 | 2.4 | 1 | |
OPM Ann. % | 13.4% | 4.8% | 10.23% | 11.56% | 13.31% | 7.01% | 7.98% | 8.08% | 3.64% | |
5.7% | 5.5% | 36.6 | 35.7 | 32.6 | 31 | 29.3 | 28 | 26.7 | ||
EBITDA Ann. | 21.1% | 16.2% | 5.5 | 5.7 | 5.7 | 3.1 | 3.3 | 2.6 | 2.1 | |
EBITDA Ann. margin % | 11.8% | 8% | 13.40% | 14.21% | 15.44% | 9.59% | 10.77% | 9.11% | 7.51% | |
Interest Ann. | -30.7% | -17.8% | 0.3 | 0.7 | 0.9 | 0.9 | 0.9 | 0.8 | 0.7 | |
Depr. | -18.3% | -5.6% | 0.6 | 0.5 | 0.5 | 1.1 | 1 | 0.8 | 0.7 | |
PBT Ann. | 33% | 36.3% | 4.7 | 4.5 | 4.7 | 2 | 0.1 | 1 | 0.7 | |
Tax Ann. | 48.1% | 34.1% | 1.3 | 1.2 | 1 | 0.4 | 0.3 | 0.3 | 0.3 | |
28.6% | 37.2% | 3.4 | 3.4 | 3.7 | 1.6 | -0.2 | 0.7 | 0.4 | ||
Net Profit Ann. | 28.6% | 37.2% | 3.4 | 3.4 | 3.7 | 1.6 | -0.2 | 0.7 | 0.4 | |
NPM Ann. % | 19.3% | 28% | 8.54% | 8.59% | 10.25% | 5.03% | -0.71% | 2.49% | 1.42% | |
EPS Adj. latest Ann. | 32% | 35.7% | 2.3 | 2.2 | 2.4 | 1 | -0.1 | 0.5 | 0.3 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
2.5%
2Y CAGR
5.8%
3Y CAGR
8.9%
5Y CAGR
7.3%
Net Profit Ann.
2Y CAGR
-4.1%
3Y CAGR
28.6%
5Y CAGR
37.2%
Operating Exp. Ann.
1Y CHG
3.5%
2Y CAGR
7.1%
3Y CAGR
7.3%
5Y CAGR
6.3%
Galaxy Medicare Technical Analysis
Galaxy Medicare EMA & SMA
Bearish-2
3 bullish, 5 bearish
Bullish3
Bearish5
| 5 Day | 18.0 |
|---|---|
| 10 Day | 18.0 |
| 12 Day | 18.0 |
| 20 Day | 17.9 |
| 26 Day | 17.9 |
|---|---|
| 50 Day | 17.9 |
| 100 Day | 18.3 |
| 200 Day | 19.7 |
Galaxy Medicare Delivery And Volume
Daily Avg. Delivery Volume %
30 Oct, 2026100.0%
Week78.6%
Month82.4%
Galaxy Medicare Active Candlesticks
Short Line Uptrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator
Galaxy Medicare Resistance and Support
18.00
Pivot
| First Resistance | 18 |
|---|---|
| Second Resistance | 18 |
| Third Resistance | 18 |
| First Support | 18 |
|---|---|
| Second Support | 18 |
| Third Support | 18 |
| Day RSI | 51 |
|---|---|
| Day MACD | 0.1 |
| Day MFI | 39.2 |
| Day MACD Signal Line | 0.1 |
Galaxy Medicare Beta
| 1 Month | 0.2 |
|---|---|
| 1 Year | - |
| 3 Month | 0.5 |
|---|---|
| 3 Year | - |
Galaxy Medicare Price Change Analysis
↑2.0%
Over 1 Month
LowHigh
16.219.1
↑7.5%
Over 3 Months
LowHigh
15.719.9
↓-5.3%
Over 6 Months
LowHigh
15.720.5
↓-14.9%
Over 1 Year
LowHigh
15.223.8
Galaxy Medicare Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| IMRAN KHAN | Bulk | Sell | 14 Oct 2025 | 23.55 | 76,000 | NSE |
| IMRAN KHAN | Bulk | Purchase | 14 Oct 2025 | 22.30 | 2,000 | NSE |
| AJAY PURSHOTTAMDAS GUPTA | Bulk | Sell | 06 Oct 2025 | 23.79 | 100,000 | NSE |
| AJAY PURSHOTTAMDAS GUPTA | Bulk | Sell | 03 Oct 2025 | 26.47 | 100,000 | NSE |
| ANMOL KESHAO HINGE | Bulk | Purchase | 03 Oct 2025 | 26.84 | 100,000 | NSE |
| VINEY GROWTH FUND | Bulk | Sell | 19 Sep 2025 | 46.35 | 80,000 | NSE |
| AJAY PURSHOTTAMDAS GUPTA | Bulk | Purchase | 17 Sep 2025 | 54 | 200,000 | NSE |
Galaxy Medicare Corporate Actions
Galaxy Medicare Dividend history and yield
Galaxy Medicare dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Galaxy Medicare dividend yield over time.
#Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
111 Sep 2026 | 0.35 | FINAL | 11 Sep 2026 | Equity Share |
217 Dec 2025 | 0.35 | INTERIM | 17 Dec 2025 | Equity Share |
Galaxy Medicare Board Meetings
Galaxy Medicare past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
129 May 2026 | Audited Results & Dividend | - |
Galaxy Medicare - Company Profile
Website: www.galaxy.com
About the company - Business Profile
Galaxy Medicare Ltd. (GML) is a provider in the medical services and pharmaceuticals sector, primarily operating through its association with other corporate entities and through direct medical service offerings. The company maintains a presence in the medical healthcare space through clinical support, pharmaceutical-related activities, and strategic financial collaborations with other industry players.
Key Points
- Key Facts:
- Founded: The entity has a long-standing history in the medical sector (exact incorporation year not specified in documents).
- Headquarters: Information not explicitly detailed in recent filings.
- Products: Pharmaceuticals, medtech segments, and medical service provisioning.
- Stock Listing: Listed on the Bombay Stock Exchange (BSE) under the symbol GML.
- Operations and Business Model:
- The company operates a medical-centric business model, leveraging its expertise in both pharmaceutical segments and medtech.
- GML serves as a financial and strategic lender to other pharmaceutical entities. For instance, it extended a financial facility of up to ₹10 crore to Alfa Transformers Ltd., which included an option for conversion into equity shares.
- The company’s operations are integrated with technical and manufacturing partners to support its medical service delivery.
- Revenue and Financial Overview (FY2024-25):
- Revenue Segmentation: For the year ended March 31, 2025, the company’s revenue was derived from two primary segments:
- Pharmaceutical Segment: Contributed significantly to the top line through the sale of medicinal products.
- Medtech Segment: Focuses on the provision of medical technology services and equipment.
- Recent Performance: In the latest fiscal year (FY25), the total segment revenue reached ₹3,679.39 lakhs (Consolidated/Standalone as per specific reports).
- Profitability: For FY25, the company reported a Profit Before Tax (PBT) of ₹1,333.66 lakhs.
- Geographical Reach: Primarily serves the domestic Indian market with select associations in export-oriented ventures.
- Revenue Segmentation: For the year ended March 31, 2025, the company’s revenue was derived from two primary segments:
- Strategic Initiatives and Outlook:
- The company is focused on the modernization of its medical tech offerings and expanding its pharmaceutical portfolio to include more niche therapeutic segments.
- GML's strategy includes leveraging its liquid assets to support industry peers through strategic lending and potential equity conversions, thereby diversifying its investment portfolio within the healthcare sector.
- Emphasis remains on maintaining high Return on Capital Employed (ROCE) through lean operational facilities and integrated service models.
- Subsidiaries and Partnerships:
- The company maintains interests in several partner companies where its directors hold key positions.
- Notable corporate relationships include Alfa Transformers Ltd. and Oricon Industries (P) Limited, where GML acts as a related party through either direct investment or common management.